Currently Viewing:
ACO & Emerging Healthcare Delivery Coalition®
Barbara Balik on Addressing Burnout and Finding Joy in Work
May 12, 2018
Dr Mark Friedberg: Clinician Burnout and Reorganization of the Practice
May 07, 2018
Dr Shantanu Agrawal Highlights Progress Being Made to Address Health Inequities
May 04, 2018
Barbara Balik: Focus on System Issues, Not the Individual, to Prevent Burnout
April 26, 2018
Dr Shantanu Agrawal: Bringing Together the Community to Tackle Social Determinants of Health
April 23, 2018
Dr Mark Friedberg Recognizes the Importance of Addressing Underlying Causes of Burnout
April 19, 2018
Dr Mark Friedberg on Achieving Professional Satisfaction in the Practice
April 11, 2018
Barbara Balik Discusses Eliminating the Negatives of EHRs
April 10, 2018
Dr Shantanu Agrawal Explains How Payment Models Can Reduce Health Disparities
April 08, 2018
Dr Justin Bachmann on the Importance of Patient-Reported Outcomes in Cardiology
February 27, 2018
Dr Justin Bachmann Discusses Cardiac Rehabilitation in Patients
February 08, 2018
Dr Justin Bachmann on How Cardiology Is Handling Transition to Value-Based Care
January 22, 2018
Dr Justin Bachmann Discusses Consequences of Value-Based Care Being Done Incorrectly
January 06, 2018
Dr Shantanu Agrawal: How Quality Measures Help to Address Health Inequities
December 31, 2017
Dr Shantanu Agrawal on the Challenge of Adjusting Measures for Social Risk Factors
December 14, 2017
Dr Mark Friedberg Discusses His Findings on Workplace Conditions in FQHCs
December 05, 2017
Barbara Balik: Why Clinician Burnout Needs to Be Addressed
November 29, 2017
Currently Reading
Clay Alspach Explains How Changes in the FDA Will Affect Biosimilars
November 27, 2017
Barbara Balik Explains the Biggest Stressors That Cause Clinician Burnout
November 19, 2017

Clay Alspach Explains How Changes in the FDA Will Affect Biosimilars

Clay Alspach, JD, principal, Leavitt Partners, explains how biosimilars will be affected by changes in the FDA under Scott Gottlieb's leadership.
 


Clay Alspach, JD, principal, Leavitt Partners, explains how biosimilars will be affected by changes in the FDA under Scott Gottlieb's leadership.

Transcript (slighly modified)

What changes in the FDA under Scott Gottlieb’s leadership do you think will have the best chance of meaningfully impacting drug prices?

It’s clear that drug pricing is a priority for President Trump, and Commissioner Gottlieb at FDA has already taken steps to prioritize generic applications. He’s also put out information on biosimilars to help educate physicians, as well as provide additional guidance for those producing them. So, I think that will be the area where they try to make the most difference.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!